Rhenman & Partners Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-15,300
| Closed | -$3.25M | – | 97 |
|
|
2024
Q3 | $3.25M | Sell |
15,300
-11,200
| -42% | -$2.38M | 0.26% | 79 |
|
|
2024
Q2 | $7.42M | Sell |
26,500
-10,000
| -27% | -$2.8M | 0.71% | 41 |
|
|
2024
Q1 | $9.75M | Buy |
36,500
+14,000
| +62% | +$3.74M | 0.92% | 39 |
|
|
2023
Q4 | $5.21M | Buy |
+22,500
| New | +$5.21M | 0.52% | 59 |
|
|
2019
Q4 | – | Sell |
-30,000
| Closed | -$2.59M | – | 98 |
|
|
2019
Q3 | $2.59M | Sell |
30,000
-7,225
| -19% | -$623K | 0.32% | 71 |
|
|
2019
Q2 | $3.9M | Buy |
37,225
+10,000
| +37% | +$1.05M | 0.43% | 62 |
|
|
2019
Q1 | $3.41M | Buy |
+27,225
| New | +$3.41M | 0.4% | 64 |
|
|
2014
Q1 | – | Sell |
-2,857
| Closed | -$524K | – | 96 |
|
|
2013
Q4 | $524K | Buy |
+2,857
| New | +$524K | 0.21% | 80 |
|